To the Editors
In their recent manuscript studying on French National Agency for Research on AIDS and Viral Hepatitis ANRS-CO16 Lymphovir cohort, Terrier et al. observed a high proportion of a distinct B-cell non-Hodgkin lymphoma (NHL) subtype in HIV/HCV-coinfected patients, when compared to HIV-monoinfected patients, in the era of combined antiretroviral therapy (cART): 5 of 6 (83%) coinfected patients versus 1 of 33 (3%) monoinfected patients presented with marginal zone/lymphoplasmacytic lymphoma (MZL/LPL). 1 These coinfected patients were more frequently intravenous drug users and had a tendency toward higher CD4 + T lymphocyte counts than HIV-monoinfected NHL patients. Patients in both groups showed comparable plasma HIV RNA concentrations. The authors described the clinical and epidemiological characteristics of HIV/HCV-coinfected NHL patients and concluded that chronic antigenic stimulation by HCV may contribute to lymphomagenesis among HIV-infected patients, resulting in the development of lymphomas of the MZL/LPL subtype. This is a striking observation, and led us to explore this hypothesis in the Multicenter AIDS Cohort Study (MACS).
The Multicenter AIDS Cohort Study (MACS), established in 1983, enrolled 6,972 men who have sex with men (MSM) from four metropolitan areas between 1984 and 2003. [2] [3] [4] [5] NHL is ascertained through self-report with confirmation by pathology records and state cancer registries, or is identified at autopsy. NHL subtypes are also defined through review of pathology reports. HCV status is determined by testing both antibodies to HCV (anti-HCV) using enzyme immunoassay (ADVIA Centaur HCV assay), and serum HCV RNA levels by PCR (COBAS AmpliPrep TaqMan HCV Assay). Anti-HCV and HCV RNA testing was performed at multiple time points retrospectively on stored serum from the baseline study visit through 2001, and prospectively every six months since 2001. Only 38 (0.6%) MACS participants had either no HCV test at all (n = 19) or inconclusive status at their enrollment visit (n = 19).
For this analysis, we examined 190 HIV-infected MACS participants diagnosed with NHL by July 2010, as described in previous studies. 6 Table 1 shows distributions of selected characteristics for NHL cases by HCV status. Most NHL cases were diagnosed in the pre-cART era, and only 14 of them, all HIVmonoinfected, received cART, with a median of 2.8 (IQR: 1.3-4.9) years from cART initiation to NHL diagnosis. All case groups had a similar distribution of HIV RNA levels at the time of NHL diagnosis (P=0.910). Among HIV/HCV-coinfected cases, more than half had their first positive results of anti-HCV and/or HCV RNA level at least 5 years prior to lymphoma diagnosis (71% and 56% of cases with cleared HCV and chronic HCV infection, respectively). A higher percentage of HIV/HCV-coinfected cases who cleared their HCV infection (71%) had NHL of the central nervous system compared to the other case groups (71% versus 29% and 22%, P=0.056). Among cases of systemic NHL, we did not observe a difference in subtype distributions across case groups (P=0.679), although sample size limits statistical power. No cases with coinfection were diagnosed with MZL/LPL. Two HIV-monoinfected cases, who never received cART, were diagnosed with lymphoplasmacytic lymphoma.
In contrast to the Terrier et al. manuscript, there were no cases of MZL/LPL among HIV/ HCV-coinfected patients in the MACS. Therefore, their suggestion that lymphomagenesis results from chronic HCV antigenic stimulation requires further study for confirmation. Further work to assess the association between HCV and specific B-cell NHL subtypes in HIV-infected populations is warranted.
There are several important differences between participants in the MACS and the French ANRS-CO16 Lymphovir cohort that should also be noted. The MACS is a population of MSM, and the NHL diagnoses were identified mainly in the pre-cART era. Only 14 participants with NHL had received cART; 7/14 (50%) of these cases had diffuse large Bcell lymphoma. One important limitation of the MACS data is a lack of tumor samples to verify subtypes via immunohistochemistry staining for all cases, as was done in the Terrier et al. paper.
cART was introduced 18 years ago, yet surprisingly only one-third of people living with HIV in the U.S. are receiving treatment. 8 While there is an ongoing HCV outbreak among HIV-infected MSM, 9, 10 very few studies have examined HCV status in patients with NHL in this population. Inspired by the recent work of Terrier et al., we presented NHL subtypes of mostly cART naïve patients by HCV status in a MSM cohort. 
